Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT131 in Treatment-Naïve RRMS
NCT02638038Phase 2Completed
- Sponsor
- InteKrin Therapeutics, Inc.
- Start
- Feb 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of INT131 in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by InteKrin Therapeutics, Inc. Primary endpoint: Number of new gadolinium CE T1 weighted lesions at 6 months. Started Feb 2015; status: completed.
02
Drugs
INT131
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02638038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638038.